LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Sana Biotechnology Inc

Closed

SectorHealthcare

2.18 -4.39

Overview

Share price change

24h

Current

Min

2.15

Max

2.19

Key metrics

By Trading Economics

Income

-320K

-49M

EPS

-0.2

Employees

194

EBITDA

-1.8M

-47M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+234.1% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

23M

449M

Previous open

6.57

Previous close

2.18

News Sentiment

By Acuity

50%

50%

151 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Sana Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 maj 2025, 10:30 UTC

Top News

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 maj 2025, 06:30 UTC

Earnings

5 Things We've Learned From Retail Earnings -- Barrons.com

31 maj 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 maj 2025, 21:30 UTC

Top News

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 maj 2025, 21:15 UTC

Top News

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 maj 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 maj 2025, 20:24 UTC

Top News

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 maj 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 maj 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 maj 2025, 19:29 UTC

Earnings
Acquisitions, Mergers, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 maj 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 maj 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 maj 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 maj 2025, 18:37 UTC

Market Talk
Earnings

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 maj 2025, 18:04 UTC

Top News

S&P 500 Falls After More Trump-China Friction -- WSJ

30 maj 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 maj 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 maj 2025, 17:40 UTC

Acquisitions, Mergers, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 maj 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 maj 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 maj 2025, 17:14 UTC

Top News

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 maj 2025, 16:31 UTC

Earnings

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 maj 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 maj 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 16:16 UTC

Top News

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 maj 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 16:14 UTC

Top News

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Peer Comparison

Price change

Sana Biotechnology Inc Forecast

Price Target

By TipRanks

234.1% upside

12 Months Forecast

Average 7.25 USD  234.1%

High 11 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forSana Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.68 / 1.87Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

151 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.